<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/4A26448B-C08D-4FE8-A6BB-E583B043506A"><gtr:id>4A26448B-C08D-4FE8-A6BB-E583B043506A</gtr:id><gtr:name>Trig1 Limited</gtr:name><gtr:address><gtr:line1>15B SOMERSET HOUSE , HUSSAR COURT WESTSIDE VIEW</gtr:line1><gtr:city>WATERLOOVILLE</gtr:city><gtr:postCode>PO7 7SG</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A26448B-C08D-4FE8-A6BB-E583B043506A" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>4A26448B-C08D-4FE8-A6BB-E583B043506A</gtr:id><gtr:name>Trig1 Limited</gtr:name><gtr:address><gtr:line1>15B SOMERSET HOUSE , HUSSAR COURT WESTSIDE VIEW</gtr:line1><gtr:city>WATERLOOVILLE</gtr:city><gtr:postCode>PO7 7SG</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>100007.0</gtr:offerGrant><gtr:projectCost>176100.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6C8DD1F4-F93C-4632-9FB6-0C8BE397EC61"><gtr:id>6C8DD1F4-F93C-4632-9FB6-0C8BE397EC61</gtr:id><gtr:firstName>Raymond</gtr:firstName><gtr:surname>Bacon</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=710192"><gtr:id>B2F1C968-1098-4718-B75C-C8FC7C8F9233</gtr:id><gtr:title>Trig1 - New Format Dose Content Indicator for Asthma Inhalers</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Concept</gtr:grantCategory><gtr:grantReference>710192</gtr:grantReference><gtr:abstractText>Pressurized metered dose inhalers (pmdis) are the most popular format for delivering life
saving medication to patients suffering from asthma and other respiratory conditions, yet it is
almost impossible for the patient to know how much drug is left in a pmdi. Indeed recent
studies have shown that it is not uncommon for patients inhalers to run out during an asthma
attack resulting in emergency hospital admissions and ambulance call outs. Regulators and
clinicians now recognize this patient difficulty and recommend/require that some form of dose
content indicator should be fitted providing the patient with enough notice to obtain a repeat
script and an indication of when the inhaler is empty. The problem addressed by this project
is the provision of just such an indicator but with minimal additional cost. Existing counters
are costly and can only be used with expensive drugs. To date in the UK only one pmdi drug
product is fitted with a counter. Of the 600 million pmdis dispensed globally per annum,
almost 50% are low cost rescue medications produced with very low profit margins. Trig1?s
low cost technology will provide a valuable potential life saving patient benefit with little or
no addition to the final product cost. The technology can be easily and quickly implemented
onto existing products as well as new products and provides the required benefit in an
extremely cost and material efficient manner providing a better and more sustainable solution.</gtr:abstractText><gtr:fund><gtr:end>2013-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2012-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>100007</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">710192</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>